Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teijin Of Japan To Do Own Development, Marketing In Asia

This article was originally published in PharmAsia News

Executive Summary

Japan's Teijin Pharma is abandoning its licensing-development course and turning to more direct involvement in developing and selling drugs in Asia. The company has been marketing drugs in China since 2006, but now plans clinical trials in China and Thailand for a new gout drug it plans to market throughout Asia. The drug TMX-67 (febuxostat) has been licensed to a South Korean firm for marketing in that country, but Teijin plans to develop and market the drug by itself in the rest of Asia, where it expects the drug to become a best-seller. Teijin also makes and markets medical equipment. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts